1. Home
  2. Pharma & Healthcare
  3. Global Drugs for Vulvovaginal Candidiasis Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Global Drugs for Vulvovaginal Candidiasis Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Publication Month: Sep 2021 | No. of Pages: 133 Published By: GRD Survey
Single User License: US $ 3980
Corporate User License: US $ 7960

Executive Summary

According to GRD Survey data, the global Drugs for Vulvovaginal Candidiasis market was valued at million US$ in 2020 and is expected to reach million US$ by the end of 2027, growing at a CAGR of % in the forecast period 2021 and 2027.

This report studies the Drugs for Vulvovaginal Candidiasis market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Drugs for Vulvovaginal Candidiasis in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Miconazole
Clotrimazole
Fluconazole
Econazole
Other

Market Snapshot, By Application
Hospital & Clinic
Pharmacy

Market Snapshot, By Region:
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
South Africa
Israel
Turkey
Saudi Arabia

Main Market Players Analyzed in this report, including:
Teva
Sanofi
Pfizer
Perrigo
Kingyork Group
J & J
Effik
Cisen Pharmaceutical
Bristol-Myers Squibb
Bayer

The study objectives of this report are:
To study and analyze the global Drugs for Vulvovaginal Candidiasis market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Drugs for Vulvovaginal Candidiasis market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Drugs for Vulvovaginal Candidiasis manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Vulvovaginal Candidiasis market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Drugs for Vulvovaginal Candidiasis submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Drugs for Vulvovaginal Candidiasis are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027

This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Drugs for Vulvovaginal Candidiasis Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Drugs for Vulvovaginal Candidiasis Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter's Five Forces Analysis
2.3 Comparison of Alternatives and Drugs for Vulvovaginal Candidiasis

3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Drugs for Vulvovaginal Candidiasis Sales Channel and Distributors Analysis
3.3.1 Drugs for Vulvovaginal Candidiasis Sales Channel
3.3.2 Drugs for Vulvovaginal Candidiasis Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Application One
3.4.2 Major Buyers in Application Two
3.4.1 Major Buyers in Application Three
3.5 Drugs for Vulvovaginal Candidiasis Manufacturing Cost Structure Analysis

4 Market Segment: by Type
4.1 Drugs for Vulvovaginal Candidiasis Type Introduction
4.1.1 Miconazole
4.1.2 Clotrimazole
4.1.3 Fluconazole
4.1.4 Econazole
4.1.5 Other
4.2 Global Drugs for Vulvovaginal Candidiasis Sales by Type 2016-2021
4.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Type 2016-2021
4.4 Global Drugs for Vulvovaginal Candidiasis Price by Type 2016-2021

5 Market Segment: by Application
5.1 Drugs for Vulvovaginal Candidiasis Type Introduction
5.1.1 Hospital & Clinic
5.1.2 Pharmacy
5.2 Global Drugs for Vulvovaginal Candidiasis Sales by Application 2016-2021
5.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Application 2016-2021
5.4 Global Drugs for Vulvovaginal Candidiasis Price by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Drugs for Vulvovaginal Candidiasis Market by Region
6.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Regions
6.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Regions
6.2 North America Drugs for Vulvovaginal Candidiasis Market 2016-2021
6.3 Europe Drugs for Vulvovaginal Candidiasis Market 2016-2021
6.4 Asia Pacific Drugs for Vulvovaginal Candidiasis Market 2016-2021
6.5 South America Drugs for Vulvovaginal Candidiasis Market 2016-2021
6.6 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market 2016-2021

7 North America
7.1 North America Drugs for Vulvovaginal Candidiasis Market by Country 2016-2021
7.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country
7.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Drugs for Vulvovaginal Candidiasis Market by Country 2016-2021
8.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country
8.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market by Country 2016-2021
9.1.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Country
9.1.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Drugs for Vulvovaginal Candidiasis Market by Country 2016-2021
10.1.1 South America Drugs for Vulvovaginal Candidiasis Sales by Country
10.1.2 South America Drugs for Vulvovaginal Candidiasis Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market by Country 2016-2021
11.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country
11.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 Teva
12.1.1 Teva Company Information
12.1.2 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.1.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 Teva Key Development
12.2 Sanofi
12.2.1 Sanofi Company Information
12.2.2 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.2.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Sanofi Key Development
12.3 Pfizer
12.3.1 Pfizer Company Information
12.3.2 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.3.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 Pfizer Key Development
12.4 Perrigo
12.4.1 Perrigo Company Information
12.4.2 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.4.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Perrigo Key Development
12.5 Kingyork Group
12.5.1 Kingyork Group Company Information
12.5.2 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.5.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Kingyork Group Key Development
12.6 J & J
12.6.1 J & J Company Information
12.6.2 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.6.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 J & J Key Development
12.7 Effik
12.7.1 Effik Company Information
12.7.2 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.7.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 J & J Key Development
12.9 Bristol-Myers Squibb
12.9.1 Bristol-Myers Squibb Company Information
12.9.2 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.9.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 Bristol-Myers Squibb Key Development
12.8 Cisen Pharmaceutical
12.8.1 Cisen Pharmaceutical Company Information
12.8.2 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
12.8.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 Cisen Pharmaceutical Key Development

13 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Region by Type and by Application
13.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue Forecast 2022-2027
13.2 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions
13.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region 2022-2027
13.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region 2022-2027
13.3 Global Drugs for Vulvovaginal Candidiasis Forecast by Type
13.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type 2022-2027
13.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type 2022-2027
13.3.3 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Type 2022-2027
13.4 Global Drugs for Vulvovaginal Candidiasis Forecast by Application
13.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application 2022-2027
13.4.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application 2022-2027
13.4.3 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Application 2022-2027

14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer


List of Tables

Table 1: Global Drugs for Vulvovaginal Candidiasis Production Specifications
Table 2: Drivers in Drugs for Vulvovaginal Candidiasis Market
Table 3: Restraints Drugs for Vulvovaginal Candidiasis Market
Table 4: Opportunity in Drugs for Vulvovaginal Candidiasis Market
Table 5: Comparion of Alternative and Drugs for Vulvovaginal Candidiasis
Table 6: Drugs for Vulvovaginal Candidiasis Raw Materials Key Suppliers List
Table 7: Drugs for Vulvovaginal Candidiasis Distributors List
Table 8: Drugs for Vulvovaginal Candidiasis Major Buyers in Application One
Table 9: Drugs for Vulvovaginal Candidiasis Major Buyers in Application Two
Table 10: Drugs for Vulvovaginal Candidiasis Major Buyers in Application Three
Table 11: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type 2016-2021
Table 12: Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type 2016-2021
Table 13: Global Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Type 2016-2021
Table 14: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type 2016-2021
Table 15: Global Drugs for Vulvovaginal Candidiasis Price by Type 2016-2021
Table 16: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application 2016-2021
Table 17: Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application 2016-2021
Table 18: Global Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Application 2016-2021
Table 19: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application 2016-2021
Table 20: Global Drugs for Vulvovaginal Candidiasis Price by Application 2016-2021
Table 21: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Region 2016-2021
Table 22: Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region 2016-2021
Table 23: Global Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Region 2016-2021
Table 24: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region 2016-2021
Table 25: North America Drugs for Vulvovaginal Candidiasis Sales (K Units) by Country 2016-2021
Table 26: North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country 2016-2021
Table 27: North America Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Country 2016-2021
Table 28: North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country 2016-2021)
Table 29: Europe Drugs for Vulvovaginal Candidiasis Sales (K Units) by Country 2016-2021
Table 30: Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country 2016-2021
Table 31: Europe Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Country 2016-2021
Table 32: Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country 2016-2021)
Table 33: Asia Pacific Drugs for Vulvovaginal Candidiasis Sales (K Units) by Country 2016-2021
Table 34: Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Country 2016-2021
Table 35: Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Country 2016-2021
Table 36: Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country 2016-2021)
Table 37: South America Drugs for Vulvovaginal Candidiasis Sales (K Units) by Country 2016-2021
Table 38: South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country 2016-2021
Table 39: South America Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Country 2016-2021
Table 40: South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country 2016-2021)
Table 41: Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales (K Units) by Country 2016-2021
Table 42: Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country 2016-2021
Table 43: Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue (Million USD) by Country 2016-2021
Table 44: Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country 2016-2021)
Table 45 Teva Company Information
Table 46 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 47 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 48 Sanofi Company Information
Table 49 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 50 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 51 Pfizer Company Information
Table 52 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 53 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 54 Perrigo Company Information
Table 55 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 56 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 57 Kingyork Group Company Information
Table 58 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 59 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 60 J & J Company Information
Table 61 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 62 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 63 Effik Company Information
Table 64 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 65 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 66 Cisen Pharmaceutical Company Information
Table 67 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 68 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 69 Bristol-Myers Squibb Company Information
Table 70 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio, Specification and Application
Table 71 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2019-2021)
Table 72: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Forecast by Region (2022-2027)
Table 73: Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2012-2027)
Table 74: Global Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Forecast by Region (2022-2027)
Table 75: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Region (2022-2027)
Table 76: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Forecast by Type (2022-2027)
Table 77: Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2012-2027)
Table 78: Global Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Forecast by Type (2022-2027)
Table 79: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Type (2022-2027)
Table 80: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Forecast by Applicaion (2022-2027)
Table 81: Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Application (2012-2027)
Table 82: Global Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Forecast by Application (2022-2027)
Table 83: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Application (2022-2027)

Tables and Figures

List of Figures

Figure 1: Drugs for Vulvovaginal Candidiasis Picture
Figure 2: Global Drugs for Vulvovaginal Candidiasis Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Drugs for Vulvovaginal Candidiasis Supply Chain Analysis
Figure 5: Drugs for Vulvovaginal Candidiasis Manufacturing Cost Structure Analysis
Figure 6: Product Picture of Miconazole
Figure 7: Product Picture of Clotrimazole
Figure 8: Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type, 2020
Figure 9: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type, 2020
Figure 10: Drugs for Vulvovaginal Candidiasis in Hospital & Clinic
Figure 11: Global Drugs for Vulvovaginal Candidiasis Market: Hospital & Clinic 2016-2021
Figure 12: Drugs for Vulvovaginal Candidiasis in Pharmacy
Figure 13: Global Drugs for Vulvovaginal Candidiasis Market: Pharmacy 2016-2021
Figure 14: Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application, 2020
Figure 15: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application, 2020
Figure 16: Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region 2016-2021
Figure 17: Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region 2016-2021
Figure 18: North America Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 19: North America Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 20: Europe Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 21: Europe Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 23: Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 24: South America Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 25: South America Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 26: Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 27: Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 28: North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country, 2020
Figure 29: North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country, 2020
Figure 30: United States Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 31: United States Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 32: Canada Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 33: Canada Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 34: Mexico Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 35: Mexico Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 36: Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country, 2020
Figure 37: Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country, 2020
Figure 38: Germany Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 39: Germany Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 40: France Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 41: France Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 42: UK Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 43: UK Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 44: Italy Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 45: Italy Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 46: Russia Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 46: Russia Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 47: Spain Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 48: Spain Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 49: Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Country, 2020
Figure 50: Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country, 2020
Figure 51: China Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 52: China Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 53: Japan Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 54: Japan Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 55: Korea Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 56: Korea Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 57: Southeast Asia Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 58: Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 59: India Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 60: India Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 61: Australia Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 62: Australia Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 63: South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country, 2020
Figure 64: South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country, 2020
Figure 65: Brazil Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 66: Brazil Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 67: Argentina Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 68: Argentina Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 69: Colombia Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 70: Colombia Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 71: Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country, 2020
Figure 72: Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country, 2020
Figure 73: Turkey Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 74: Turkey Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 75: Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 76: Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 77: South Africa Drugs for Vulvovaginal Candidiasis Sales (K Units) Status 2016-2021
Figure 78: South Africa Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Status 2016-2021
Figure 79: Teva Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 80: Sanofi Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 81: Pfizer Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 82: Perrigo Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 83: Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 84: J & J Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 85: Effik Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 86: Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 87: Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 88: Bayer Drugs for Vulvovaginal Candidiasis Revenue Market Share Globally (2019-2021)
Figure 89: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Forecast (2022-2027)
Figure 90: Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Forecast (2022-2027)


Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets